• Gram-positive, spore-forming, anaerobic bacterium
• Leading cause of hospital-acquired diarrhea in developed countries
• C. Difficile infection (CDI) affects approximately 500,000 individuals and causes more than 20,000 deaths and more than $1 billion in healthcare costs annually in the United States
• Current antibiotic therapy is associated with incomplete response or disease recurrence in approximately 30% of patients
• Main virulence factors are toxin A and toxin B

• Human mAbs for prevention and treatment of C. Difficile infection
• Fully human mAbs derived from human B-lymphocytes
• IgG1 Abs
• Demonstrated efficacy in vitro and in animal model of C. Difficile infection

IMR-90 cells were added to 96-well plates at 3.5 ×10⁴ cells per well. Toxin A (20 ng/ml) was combined with serially diluted mAbs for 1hour at 37C and then added to the cells. After incubation for 24 hours, percentages of rounding cells were determined.

• Family Paramyxoviridae, Subfamily Pneumovirinae
• Related genetically to respiratory syncytial virus (RSV)
• Two serotypes were identified, each of which represents 2 lineages (A1, A2, B1, and B2, respectively), which are also reflected by genetic diversity of the virus
• About 10% of children hospitalized with acute respiratory tract infections suffer from MPV infection
• A major cause of severe and sometimes even fatal respiratory infections in immunocompromised patients
• Fusion (F) protein is the most important target of protective immunity

• Human mAbs for prevention and treatment of hMPV infection
• 13 independent fully human mAbs derived from human B-lymphocytes
• IgG1 Abs
• Demonstrated efficacy in vitro

• A ubiquitous nuclear protein
• Released from cells during innate immune response, apoptosis and necrosis
• Sepsis
  • HMGB1 acts as a cytokine that mediates organ damage in sepsis
    Sepsis is systemic inflammation caused by infections. In the United States, sepsis is the third leading cause of death and accounts for 9% of all deaths
• Neuropathic pain
  • HMGB1 is released after nerve injury and contributes to the development of neuropathic pain

• Humanized mAb
• IgG1, λ
• Binds HMGB1, but not HMGB2
• Binds all types of HMGB1
• Inhibits HMGB1 binding to RAGE
• Effective in animal disease models of sepsis

S6 and G4 are anti-HMGB1 human Abs from Medimmune, and were produced by Evec, Inc. for direct comparison